Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EFTR NASDAQ:GNCA NYSE:NAVB NASDAQ:PXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEFTReFFECTOR Therapeutics$0.00+200.0%$0.00$0.00▼$0.02$1K2.45,752 shs17,971 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/ANAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shsN/APXMDPaxMedica$0.00$0.00$0.00▼$0.02$6K-0.994,717 shs151 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEFTReFFECTOR Therapeutics+200.00%+200.00%0.00%+200.00%+100.00%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%PXMDPaxMedica0.00%0.00%-28.57%-28.57%+400.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEFTReFFECTOR Therapeutics$0.00+200.0%$0.00$0.00▼$0.02$1K2.45,752 shs17,971 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/ANAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shsN/APXMDPaxMedica$0.00$0.00$0.00▼$0.02$6K-0.994,717 shs151 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEFTReFFECTOR Therapeutics+200.00%+200.00%0.00%+200.00%+100.00%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%PXMDPaxMedica0.00%0.00%-28.57%-28.57%+400.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEFTReFFECTOR Therapeutics 0.00N/AN/AN/AGNCAGenocea Biosciences 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/APXMDPaxMedica 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEFTReFFECTOR TherapeuticsN/AN/AN/AN/A($1.94) per shareN/AGNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00NAVBNavidea Biopharmaceuticals$8.13K0.00N/AN/AN/ANaNPXMDPaxMedicaN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEFTReFFECTOR Therapeutics-$35.81M-$13.08N/AN/AN/AN/AN/AN/A8/12/2026 (Estimated)GNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/ANAVBNavidea Biopharmaceuticals-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/APXMDPaxMedica-$18.29M-$6.09N/AN/AN/AN/A-3,167.89%-560.35%9/2/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/APXMDPaxMedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEFTReFFECTOR TherapeuticsN/AN/AN/AGNCAGenocea Biosciences0.241.351.35NAVBNavidea BiopharmaceuticalsN/AN/AN/APXMDPaxMedicaN/A0.380.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEFTReFFECTOR Therapeutics57.67%GNCAGenocea Biosciences0.64%NAVBNavidea Biopharmaceuticals0.01%PXMDPaxMedica4.90%Insider OwnershipCompanyInsider OwnershipEFTReFFECTOR Therapeutics4.70%GNCAGenocea Biosciences1.61%NAVBNavidea Biopharmaceuticals43.68%PXMDPaxMedica1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionNo DataPXMDPaxMedica211.31 million11.20 millionNot OptionableEFTR, NAVB, GNCA, and PXMD HeadlinesRecent News About These CompaniesPaxMedica, Inc. (PXMD) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comPaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other ConditionsJanuary 14, 2025 | accesswire.comAStudy Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD PatientsSeptember 23, 2024 | msn.comBioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884KSeptember 3, 2024 | msn.comPaxMedica Secures Immediate Exercise of WarrantsSeptember 3, 2024 | accesswire.comAYale Study Unravels Autism, Brain Growth PatternsSeptember 1, 2024 | msn.comPaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionAugust 27, 2024 | finanznachrichten.dePaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionAugust 27, 2024 | accesswire.comAPaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101May 15, 2024 | globenewswire.comPXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024May 13, 2024 | investorplace.comPaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyMay 7, 2024 | markets.businessinsider.comPaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyMay 7, 2024 | finance.yahoo.comPaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDAMay 3, 2024 | theglobeandmail.comPaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastApril 26, 2024 | finance.yahoo.comUrgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in MalawiApril 25, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDAApril 25, 2024 | theglobeandmail.comPaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101April 23, 2024 | globenewswire.comPaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping SicknessApril 18, 2024 | finanznachrichten.deChoosing Unknown Penny Stocks, 3 Top TipsApril 15, 2024 | pennystocks.comPPaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA SubmissionApril 12, 2024 | finanznachrichten.deNew MarketBeat Followers Over TimeEFTR, NAVB, GNCA, and PXMD Company DescriptionseFFECTOR Therapeutics NASDAQ:EFTR$0.0006 +0.00 (+200.00%) As of 06/26/2026 11:05 AM EasterneFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Genocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.Navidea Biopharmaceuticals NYSE:NAVBNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.PaxMedica NASDAQ:PXMD$0.0005 0.00 (0.00%) As of 06/26/2026 02:17 PM EasternPaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
